AgeneBio CEO Jerry McLaughlin to Present at Biotech Showcase 2015

Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates to treat patients with neurological and psychiatric disease.

« back to Press Releases

January 7, 2015

AgeneBio CEO Jerry McLaughlin to Present at Biotech Showcase 2015

BALTIMORE, MD January 7, 2015 /PR Newswire/ — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling amnestic mild cognitive impairment (aMCI), the pre-dementia phase of Alzheimer’s disease, and other neurological and psychiatric diseases, today announced that the Company will present at the 7th Annual Biotech Showcase 2015. Jerry McLaughlin, AgeneBio’s president and CEO, will present to Biotech Showcase on Tuesday, January 13, 2015, at 9 am Pacific time (noon Eastern time) at the Parc 55 Wyndham San Francisco – Union Square.

A live webcast of the presentation will be available on the Investor Relations section of the AgeneBio website at www.agenebio.com. A webcast replay will be available approximately two hours after the presentation.

Biotech Showcase will take place at the Parc 55 Wyndham San Francisco-Union Square January 12 to 14, 2015. Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to investors and pharmaceutical executives during one of the industry’s largest annual healthcare investor conferences.

About aMCI, the Pre-Dementia Phase of Alzheimer’s Disease
Today 5.6 million Americans and 25 million people globally suffer from amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia phase of Alzheimer’s disease characterized by significant loss of memory, and this population will double by 2030. By age 85, one of every three people will have Alzheimer’s disease. Alzheimer’s disease currently costs Medicare and Medicaid $150 billion in direct medical costs annually with the cost expected to exceed $1 trillion by 2050. Data from the National Institute on Aging show that modest delays have massive benefits to patients, their families, and society as a whole. If the onset of Alzheimer’s dementia can be delayed, there is an approximately 10% reduction in the prevalence of this disease for every one-year delay in the onset of Alzheimer’s dementia.

About AgeneBio
AgeneBio is an emerging pharmaceutical company dedicated to developing innovative therapeutics that prevent neurodegeneration and preserve and restore cognitive function for unserved patients battling amnestic mild cognitive impairment (aMCI), the symptomatic pre-dementia phase of Alzheimer’s disease, and other neurological and psychiatric diseases. AgeneBio’s novel pipeline of therapies is based on decades of research at Johns Hopkins University and leading research centers worldwide showing that overactivity in the hippocampus contributes to cognitive impairment and drives neurodegeneration if not controlled. This overactivity is a characteristic feature of aMCI. If approved, AgeneBio’s Phase 3-ready lead candidate, AGB101, will be the first and only therapeutic targeting hippocampal overactivity and potentially the first therapeutic to slow progression to, and delay the onset of, Alzheimer’s dementia. AgeneBio also has a novel GABAA α5 small molecule program in late discovery stage with potential therapeutic potential for a spectrum of untreated conditions including aMCI, autism and schizophrenia. Learn more at www.agenebio.com.

Media Contacts:

Hilary Lefebvre
press@agenebio.com
212.300.4929

Jennifer Guinan
Sage Strategic Marketing
Jennifer@sagestrat.com
610.410.8111